Latest news with #Revive
Associated Press
4 days ago
- Business
- Associated Press
Revive Therapeutics Advances with Next-Generation Bucillamine Development
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ('Revive' or the 'Company') (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, is pleased to announce the advancement of its next-generation lyophilized formulation of Bucillamine ('New Bucillamine'). Developed in collaboration with the esteemed University of Waterloo, this breakthrough aims to address significant unmet medical needs and unlock substantial value for shareholders. Strategic Development Targeting High-Value Opportunities Revive is strategically positioning New Bucillamine to target public health emergencies such as pandemic influenza and emerging infectious diseases. Additionally, the company will pursue FDA incentives, including Emergency Use Authorization, Orphan Drug Designation, Fast Track, and Breakthrough Therapy designations, maximizing the potential for rapid market entry and revenue generation. Highlighting its potential, Bucillamine, a potent antioxidant and anti-inflammatory, already boasts FDA Orphan Drug Designation for ischemia-reperfusion injury following solid organ transplantation. This designation, awarded in 2022, underscores the compound's promise and provides a pathway to accelerated development and commercialization. Furthermore, research suggests Bucillamine may enhance solid tumor treatments in cancer and the Company has been contacted by a prominent clinical researcher from a U.S. University Cancer Institute to investigate Bucillamine for boosting anti-tumor effects in patients with advanced solid tumors, potentially opening up another significant market segment. Strong Partnerships and Ongoing Research Driving Growth Revive is committed to fostering strong pharmaceutical and government collaborations to accelerate New Bucillamine's clinical and commercial development. Currently, the company is working with Defence R&D Canada – Suffield Research Centre (DRDC), part of the Canadian Department of National Defence, on a study evaluating Bucillamine for nerve agent exposure. Positive results, expected by June 2025, could pave the way for human clinical trials in the second half of 2025 and subsequent FDA and Health Canada approvals. The potential applications of Bucillamine extend to traumatic brain injury and viral infections, further expanding its market potential and long-term value for investors. Revive also reports that it is continuing to work with LTS Lohmann Therapie-System AG to settle the previously announced arbitration award. About Revive Therapeutics Ltd. Revive Therapeutics is a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs. Revive strategically prioritizes its drug development pipeline to leverage FDA regulatory incentives like Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations, positioning for rapid advancement and market entry. Currently, our efforts are concentrated on unlocking the vast potential of Bucillamine for infectious diseases and medical countermeasures, including the pioneering treatment of nerve agent exposure. Furthermore, Revive is vigorously advancing our Psilocybin and molecular hydrogen therapeutic programs, exploring new frontiers in medical science. For more information, visit For more information, please contact: Michael Frank Chief Executive Officer Revive Therapeutics Ltd. Tel: 1 888 901 0036 Email: [email protected] Website: Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement
Epoch Times
23-05-2025
- Business
- Epoch Times
Aussie Streaming Quotas Could Divert $200 Million From Hollywood: Trump Official
Australia has been named as one of several governments that 'undercut' the U.S. film industry, according to a social media post by a top U.S. trade official. On May 23, U.S. Trade Representative Jamieson Greer wrote about the Trump administration's efforts to bring big budget Hollywood productions back onshore, appointing 'special ambassadors to Hollywood' to try kickstart the initiative. The move comes after the administration approved a 'Over 80 countries offer production tax incentives, resulting in many productions that could have been filmed in the United States locating elsewhere,' Greer 'Many blockbusters have been filmed in Canada, Croatia, France, New Zealand, and several other countries, which offer generous incentives, while overall production in the U.S. was down 26 percent in 2024 compared to 2021.' Greer named the Australian Labor government's impending National Cultural Policy 'Revive.' Related Stories 4/29/2025 4/10/2025 'Australia's National Cultural Policy, released in January 2023, recommends imposing Australian screen content requirements on streaming video services,' he said. According to Greer, these rules could lead U.S.-based platforms spending between $220 million and $440 million annually in Australia, instead of in the United States. The Hollywood sign in Los Angeles on Nov. 16, Are the Current Quotas? Content quotas require broadcasters and digital platforms to invest or broadcast a specified amount of local content, aimed at maintaining the local culture. Revive earmarks a production expenditure model where streaming companies need to spend a portion of locally derived revenue—up to 30 percent for the largest platforms—on Australian drama. The other suggestion is mandating that 10 percent be invested in new local productions, which could later rise to 20 percent. The policy remains under development. 'Countries typically rely on tools like local content quotas. For example, France and Australia have requirements for domestic content on radio and streaming platforms, and China restricts access to foreign film licenses through a strict annual cap,' said Vladimir Tyazhelnikov, senior lecturer in economics and specialist in global tariffs, in The Epoch Times has reached out to Tony Burke, the minister for art and culture for latest reaction but did not receive a response in time for publication. During Senate Estimates in May 2024, officials from the Department of Communications confirmed that the Revive proposal was still being refined ahead of Cabinet consideration. The issue hit a roadblock when trade experts and industry representatives raising concerns that the proposed quotas might violate terms of the Australia–United States Free Trade Agreement (AUSFTA). Australia's Response So Far Australia's ambassador to Washington, former Labor Prime Minister Kevin Rudd, recently flagged concerns over the 100 percent tariff on imported films. Speaking at a public forum, Rudd warned such a move could hinder cultural exchange. 'I don't think we want to see a tax on Bluey,' he said, referencing the Brisbane-made children's show that has become the most streamed program in the United States. Meanwhile, some local experts are concerned of the impact it could have on the Australian industry, given its heavily reliance on U.S. productions. 'The impact on Australia would be swift and severe. States such as New South Wales and Queensland have built robust screen production industries, attracting major international projects such as Thor: Love and Thunder, Elvis, Shang-Chi and the Legend of the Ten Rings, and The Fall Guy,' said Mike Seymour, an Emmy-nominated visual effects professional and senior lecturer at the University of Sydney Business School. 'These productions inject millions into local economies and support a wide network of jobs in everything from set design and location services to visual effects and post-production. 'When Australian screen content is under pressure because of the rise of global streamers and the decline of free-to-air broadcasting, these international partnerships are more important than ever.'
Yahoo
12-05-2025
- Health
- Yahoo
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ('Revive' or the 'Company') (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure. This study is conducted in partnership with Defence R&D Canada – Suffield Research Centre ('DRDC'), an agency of the Canadian Department of National Defence, which brings a wealth of expertise and resources to the project. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. After recent discussions with the DRDC, the research study on Bucillamine is now set to conclude by June 2025, focusing on GABA receptor antibodies and data confirmation for effect size. Positive outcomes may accelerate human clinical trials in the second half of 2025, aiming for FDA and Health Canada approvals for treating nerve agent or organophosphate pesticide poisoning. Additionally, Bucillamine's potential in traumatic brain injury from concussive/explosive forces and viral infections is under agents are chemicals that affect the nervous system. Nerve agents are highly toxic regardless of the route of exposure. The main chemical nerve agents that are man-made and manufactured for use in chemical warfare are sarin, soman, tabun and VX. These nerve agents are known to be present in military stockpiles. Exposure to nerve agents can occur due to chemical warfare or accidental release from a military storage facility. Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors, and death. Recent studies have shown that antioxidant compounds such as n-acetylcysteine ('NAC') could be beneficial in limiting seizure activity and improving the anticonvulsant efficacy of GABA-mediating drugs such as diazepam. Bucillamine is a significantly more effective antioxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC. The overall objective of the research project is to investigate pharmacological means for neuroprotection of GABA(A) receptors, which are required for the effectiveness of currently fielded anticonvulsant therapies. Bucillamine and NAC will be evaluated to determine the effect on GABA(A) receptor endocytosis and the effect on diazepam effectiveness in terminating seizures. Any additional antioxidant effects on seizure activity and survival will also be assessed. About Revive Therapeutics Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin and molecular hydrogen therapeutics through various programs. For more information, visit For more information, please contact: Michael FrankChief Executive OfficerRevive Therapeutics 1 888 901 0036Email: mfrank@ Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words 'may', 'could', 'intend', 'expect', 'believe', 'will', 'projected', 'estimated' and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive's current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company's cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading 'Risk Factors' in the Company's management's discussion and analysis for the three and six months ended December 31, 2024 ("MD&A"), dated February 24, 2025, which is available on the Company's profile at
Forbes
12-05-2025
- Business
- Forbes
The Founder's Edit: Allison Lee –The Visionary Leading The Charge In Fashion Sustainability
Allison Lee, Founder & CEO of Revive Revive In the world of fashion innovation, one name is quickly rising to the forefront: Allison Lee, founder of Revive, a Forbes 30 Under 30 honoree. Lee, a Korean immigrant who arrived in the U.S. at the age of 13, has a journey to entrepreneurial success marked by reinvention, perseverance, and a clear purpose. Graduating with a degree in psychology from the University of California, Berkeley, Lee had no intention of following a traditional career path. Despite the influence of her father, a psychiatrist, and the typical Asian family expectation to pursue a career in finance, medicine, or law, Lee knew she belonged in the exciting world of tech startups and entrepreneurship. After several roles with tech startup firms, Lee followed her passion and founded Hemster. Hemster focused on providing retailer alteration services, a unique niche that utilizes technology to capture personalized fit data, streamlining the tailoring process for omnichannel brands. Raising her first round of funding was a monumental challenge as Lee had no connections in the venture capital space. As a young female Asian American founder, she also faced the added barriers of unconscious bias and skepticism from investors. Lee persisted, knowing that the road to success would not be easy. Despite the odds, she successfully obtained her first round of funding, and Hemster began to thrive. However, when the pandemic struck, Hemster's model of offering in-person alteration services experienced a sharp decline. Like many other entrepreneurs faced with a sudden disruption, Lee took the pandemic as an opportunity to rethink her approach and pivot flexibly. Instead of wiping the board and starting from scratch, she asked herself: What was an issue within the fashion industry that she was uniquely positioned to solve—and how could she utilize Hemster's existing data science infrastructure to provide a solution? That was the lightbulb moment for Lee as she realized retailers face significant return, markdown, and loss rates due to damaged or slightly imperfect merchandise. Items that are often still in good condition but deemed unsellable. Returns and waste have become a significant problem in the fashion industry. Studies indicate that the retail sector generates approximately 92 million tons of textile waste annually. This waste incurs substantial environmental and financial costs due to overproduction and the fast fashion model. Retailers lose billions of dollars from returns, and many items ultimately end up in landfills, contributing to a $500 billion waste crisis each year. Lee's keen observation inspired her to create Revive, a company that restores these damaged items instead of discarding them. Leveraging the data science infrastructure she had built with Hemster, Lee turned her attention to refurbishing and reselling these damaged items. Revive allowed her to provide brands a new way to salvage lost inventory, reduce waste, and contribute to a more sustainable and profitable fashion ecosystem. Revive generates revenue by partnering with brands to receive unsellable returns, which are then assessed using data science to determine the damage and set a refurbishment budget per item. Once the budget is approved, items are repaired by vetted contractors and vendors who meet ethical and environmental standards. Brands are given the first opportunity to resell the refurbished goods at full price. Any unsold items are listed on Revive's marketplace, including platforms like eBay and ThredUp, with Revive taking a commission on those sales. This model generates a sustainable revenue stream through service fees for refurbishment and commissions from reselling, helping reduce the fashion industry's growing waste problem. With the launch of Revive in 2023, Lee quickly proved that sustainability could be profitable. Through partnerships with global brands, Revive became the go-to solution for inventory management and product refurbishment. The company's growth was staggering—46x in just 11 months—surpassing even Lee's own expectations. Growth wasn't just about numbers. For Lee, it was validation that the market was ready for a sustainable, data-driven company that minimized waste and maximized value. Revive helped brands recover lost revenue and move towards a more sustainable future by providing them with the solution to refurbish and resell damaged goods. In 2024, Lee found the second round of fundraising for Revive to be much easier. With a proven track record, stronger connections, and a more experienced team, she successfully raised $3.5 million in funding. This milestone highlighted her resilience, knowledge, and confidence. Lee's successful journey illustrates the true essence of a founder. Overcoming adversity as an immigrant and raising funds, she has become a Founder and CEO, a pioneering Asian female leader in a male-dominated industry. Her journey demonstrates that perseverance and hard work can break barriers. More importantly, Lee believes that success is not just about making money but also about discovering her purpose. Allison Lee's story is a reminder that true innovation involves navigating uncertainty, embracing failure, and ultimately forging your path. Lee's advice to aspiring entrepreneurs—especially young women of color—is straightforward: "If you're meant to be doing something, you will know it. Don't be afraid to take risks, but be prepared to face the challenges. Entrepreneurship is not glamorous, but it is incredibly rewarding."
The Sun
07-05-2025
- Entertainment
- The Sun
BGT judge Amanda Holden launches money-spinning new venture set to rake in millions – and it's worlds away from TV
BRITAIN'S Got Talent judge Amanda Holden has launched a money-spinning new venture set to rake in millions - and it's worlds away from TV. Having long been one of Britain's best-loved presenters, Amanda, 54, is now turning her talents to the beauty world with the launch of her very own brand. Known for her incredible figure and glowing complexion, Amanda is often praised for her flawless appearance – which she puts down to yoga, healthy eating and regular facials. She's already the face of collagen brand Revive, but now she's stepping out solo with a glamorous new project. The Heart radio host has officially set up ALH Beauty Ltd, a company named after her initials – Amanda Louise Holden – and registered to sell cosmetics and toiletries in specialist stores. Hints about her new direction first surfaced last month when Amanda posted a cryptic Instagram photo of her feet soaking in a spa bath before plunging them into a bucket of ice water, banana in hand. She cheekily captioned it: 'This is what my #innercircle currently looks like.' Shortly after, she shared more snaps showing herself in full old-Hollywood glam – applying lipstick, rocking a smoky eye, and donning sparkling earrings – alongside a shot of a luxe-looking eyeshadow palette. One photo showed her beaming, with the caption promising that her 'inner circle' is coming soon, teasing a major beauty launch. But that's not the only business move Amanda's made recently. Amanda and Alan Carr's Spanish renovated townhouse has sold for a huge six-figure profit. Following the success of their previous renovations in Sicily and Tuscany, the third season of BBC One's Amanda and Alan's Spanish Job. saw the pair headed to the historic village of Moclín. The best friends soaked up some Spanish sun as they renovated a run-down townhouse that had been uninhabited for decades. And, recently, the property went under offer for a six-figure sum - just one month after going on the market. They initially bought the derelict building for €65,000 (£55,000), and was put on the market for £208,355 just a few weeks ago. One lucky buyer snapped up the three-bedroom house, with all profits going to Comic Relief and Children in Need. 4 4
